Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
COO 
The Cooper Companies, Inc (COO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: COO (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $84.47
1 Year Target Price $84.47
| 9 | Strong Buy |
| 2 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.16% | Avg. Invested days 52 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.95B USD | Price to earnings Ratio 31.94 | 1Y Target Price 84.47 |
Price to earnings Ratio 31.94 | 1Y Target Price 84.47 | ||
Volume (30-day avg) 19 | Beta 0.97 | 52 Weeks Range 61.77 - 112.29 | Updated Date 09/16/2025 |
52 Weeks Range 61.77 - 112.29 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-27 | When After Market | Estimate 1.07 | Actual 1.1 |
Profitability
Profit Margin 10.08% | Operating Margin (TTM) 16.57% |
Management Effectiveness
Return on Assets (TTM) 3.79% | Return on Equity (TTM) 5.01% |
Valuation
Trailing PE 31.94 | Forward PE 14.86 | Enterprise Value 15307789292 | Price to Sales(TTM) 3.2 |
Enterprise Value 15307789292 | Price to Sales(TTM) 3.2 | ||
Enterprise Value to Revenue 3.78 | Enterprise Value to EBITDA 14.03 | Shares Outstanding 198808992 | Shares Floating 197506723 |
Shares Outstanding 198808992 | Shares Floating 197506723 | ||
Percent Insiders 0.61 | Percent Institutions 104.06 |
Upturn AI SWOT
The Cooper Companies, Inc
Company Overview
History and Background
The Cooper Companies, Inc. was founded in 1958. Initially involved in a variety of businesses, it evolved to focus primarily on contact lenses and women's health. Significant milestones include acquisitions that expanded its market presence and product portfolio.
Core Business Areas
- CooperVision: Develops, manufactures, and markets a wide range of contact lenses for various vision correction needs, including spherical, toric, multifocal, and specialty lenses.
- CooperSurgical: Provides a range of products and services focused on women's health, including fertility solutions, surgical instruments, and diagnostic products.
Leadership and Structure
The leadership team consists of a CEO, CFO, and other executive officers responsible for managing the company's operations. The organizational structure is typically divided by business segment (CooperVision and CooperSurgical) with functional departments supporting each segment.
Top Products and Market Share
Key Offerings
- MyDay Contact Lenses: A daily disposable contact lens known for its comfort and breathability. CooperVision holds a significant share of the daily disposable lens market. Competitors include Alcon (ALC), Johnson & Johnson (JNJ), and Bausch + Lomb (BLCO).
- Avaira Vitality Contact Lenses: A monthly disposable contact lens. CooperVision holds a substantial market share of the monthly lens market. Competitors include Alcon (ALC), Johnson & Johnson (JNJ), and Bausch + Lomb (BLCO).
- Paragard IUD: A non-hormonal intrauterine device for contraception. CooperSurgical has a strong presence in the IUD market. Competitors include Bayer (BAYRY).
- Origio: Assisted Reproductive Technology (ART) products. The company is a leader in this space. Competitors include Merck (MRK).
Market Dynamics
Industry Overview
The contact lens market is characterized by ongoing innovation in materials and designs, driven by increasing demand for vision correction and convenience. The women's health market is expanding due to increased awareness of reproductive health and technological advancements in fertility treatments and surgical procedures.
Positioning
The Cooper Companies, Inc. is a leading player in both the contact lens and women's health markets. Its competitive advantages include a strong brand reputation, a diversified product portfolio, and a global distribution network.
Total Addressable Market (TAM)
The global contact lens market is estimated to be worth tens of billions of dollars. The global women's health market is even larger, with projections reaching hundreds of billions of dollars. Cooper Companies is well-positioned to capture a significant share of these markets.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in both contact lenses and women's health
- Diversified product portfolio
- Global distribution network
- Consistent revenue growth
- History of successful acquisitions
Weaknesses
- High debt levels
- Dependence on key products
- Exposure to regulatory risks
- Potential supply chain disruptions
- Competitive pressure from larger players
Opportunities
- Expanding into emerging markets
- Developing innovative products and technologies
- Acquiring complementary businesses
- Increasing market share in existing segments
- Leveraging digital channels for marketing and sales
Threats
- Intense competition from established players
- Changes in consumer preferences
- Economic downturns
- Regulatory changes in healthcare
- Product liability claims
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- BAYRY
- MRK
- BLCO
Competitive Landscape
The Cooper Companies, Inc. competes with larger, more diversified healthcare companies. It differentiates itself through a focus on innovation and a strong brand reputation.
Major Acquisitions
Mycon Medical, Inc.
- Year: 2023
- Acquisition Price (USD millions): 60
- Strategic Rationale: Expanding CooperSurgical's portfolio of medical devices focused on women's health.
Growth Trajectory and Initiatives
Historical Growth: The Cooper Companies, Inc. has demonstrated consistent growth through organic expansion and strategic acquisitions.
Future Projections: Analyst estimates project continued growth in revenue and earnings, driven by increasing demand for contact lenses and women's health products.
Recent Initiatives: Recent initiatives include new product launches, acquisitions of complementary businesses, and investments in research and development.
Summary
The Cooper Companies is a solid player in the contact lens and women's health markets, displaying consistent revenue growth and strategic acquisitions. The company is heavily in debt which offsets the positives of the company. It should continue to innovate and grow within these markets. Watch out for regulatory and competitive pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q)
- Company press releases
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data and analyst estimates are subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About The Cooper Companies, Inc
Exchange NASDAQ | Headquaters San Ramon, CA, United States | ||
IPO Launch date 1983-12-30 | President, CEO & Non-Independent Director Mr. Albert G. White III | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 16000 | Website https://www.coopercos.com |
Full time employees 16000 | Website https://www.coopercos.com | ||
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia; and spherical lense, including lenses that correct near and farsightedness in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including paragard contraceptive intrauterine devices; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.